SARS-CoV-2 Coronavirus COVID Vaccine Market Analysis & Forecast Report to 2026

SARS-CoV-2 Coronavirus COVID Vaccine Market Analysis & Forecast Report to 2026

4,24112,723

COVID Vaccine Market Report Includes:

  • Financial market forecast through 2026 with CAGR values of all market segments – vaccine technology, geography (US, EU, UK, Japan, RoW) & major players
  • Global COVID vaccine market analysis, vaccine technology breakdown & leading market players – Pfizer, BioNTech, Moderna, AstraZeneca, J&J, NovaVax, Sinovac, Gamaleya
  • Advance purchase agreements, marketed products, financial analysis & business strategy
  • Focus on current trends, business environment, pipeline products, clinical trials
  • Insight into challenges faced by stakeholders, particularly manufacturers & governments
  • Influence of the molecular diagnostics, PCR testing & POC testing landscapes
  • Insight into the emergence of variants & impact on vaccine effectiveness & the overall market

For more information or complimentary sample pages please email deirdre@kellysci.com

Clear

Description

SARS-CoV-2 Coronavirus COVID Vaccine Market Analysis Report & Forecast to 2026

The SARS-CoV-2 Coronavirus COVID vaccine market analysis report provides a comprehensive overview of the size of the SARS-CoV-2 COVID Vaccine market, segmentation of the industry (by geography and vaccine technology), key players and the vast potential of vaccines that are in clinical trials. The key players dominating the COVID vaccine market at present include Pfizer, BioNTech, Moderna, AstraZeneca and J&J. Our analysis indicates that the global COVID vaccine market was worth over $59 billion in 2021. However, our senior analysts forecast that an initial drop will occur in 2022 due to a number of factors including single booster shots as opposed to two shot vaccines and reduced prices in vaccines due to competition.

How Will the COVID Vaccine Market Grow in an Endemic Phase to 2026?

The COVID vaccine industry is expected to then grow significantly at a CAGR of over 9% and reach $47.5 billion by 2026. This is due to an opening up of the market from a closed government-dominated space to one in which private healthcare providers and companies can purchase vaccines. There will also be a continued significant un-met need for vaccine boosters in an endemic situation.

Challenges of Mutations and Threats of Future Variants to the Vaccine Market

The emergence of SARS-CoV-2 spike protein mutations globally have enabled the virus to become more infectious. Sequencing thousands of samples have enabled the identification of the most common mutations thus far including B.1.1.7 (UK), B.1.351 (South Africa) and P1 lineage (Japan/Brazil). Mutations such as these give the virus an evolutionary advantage for selection as they allow for protein structural changes in the spike protein. This is most notable in Ireland which had a 5% prevalence of the B.1.1.7 strain in December 2020, which increased dramatically to 90% prevalence by February 2021. The B.1.1.7 strain contains numerous mutations in the spike region which give it a higher affinity to attach to human cells. Studies to date estimate that this variant is between 30-50% more infectious than the original strain.

Will this Have an Effect on the Efficacy of Vaccines?

Mutations arising in the spike protein of variants pose a potential problem for the efficacy of vaccines. This is due to the fact that vaccines to date target the spike protein, and so neutralizing antibodies and the T cell response are primed against the original spike protein structure. With regards the South African B1.351 variant, serum from individuals who received the Moderna mRNA-1273 vaccine were shown to have lower neutralization ability in in vitro assays. However, even though neutralization ability was lower, it was still significant.

A similar study demonstrated that neutralization of a virus containing three mutations from the South African variant from sera from individuals vaccinated with Pfizer/BioNTech BNT162b2 was lower than the UK variant. However, the study indicated that differences in neutralization was very small. This study indicates that the Pfizer/BioNtech vaccine still works against the South African strain, but is slightly less effective. Similarly, the AstraZeneca, Novavax and J&J vaccines also show slightly less protection.

A recent report in the New England Journal of Medicine evaluated a study group of 596,618 vaccinated people (matched to unvaccinated controls) in Israel for BNT162b2 COVID vaccine effectiveness. Their results indicated that BNT162b2 vaccination is highly effective in a real world population, and mirrors clinical trial results thus far.

This report describes the evolution of such a huge market in 8 chapters supported by over 74 tables and figures in over 137 pages.

The report focuses on the following:

  • An overview of the SARS-CoV2 virus that includes: genetic and structural analysis, mutation and variant characterization
  • Global COVID vaccine market, global landscape analysis, vaccine technology breakdown and leading market players
  • Advance purchase agreements, marketed/pipeline products, financial analysis and business strategy of the major companies in this space
  • Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for COVID vaccines to 2026
  • Clinical trial timelines for major vaccines in the pipeline
  • Insight into the challenges faced by stakeholders, particularly manufacturers and governments
  • Insight into the emergence of variants and their impact on vaccine effectiveness and the overall market
  • Financial market forecast through 2026 with CAGR values of all market segments – vaccine technology, geography (US, EU, UK, Japan, RoW) and major players
  • Influence of the molecular diagnostics, PCR testing and POC testing landscapes
  • Numbers of vaccine doses available by each manufacturer per annum
  • Geographical analysis and challenges within countries with respect to advance purchase agreements and distribution channels

 

For more information or complimentary sample pages please email deirdre@kellysci.com

 

Additional information

Licence Types

Enterprise Wide Licence, Mid Level Licence (up to 10 people), Single User Licence

Table of Contents

SARS-CoV-2 COVID Vaccine Market Analysis & Forecast Report

1.0         SARS-CoV-2 Pandemic Introduction

1.1         Emergence of SARS-CoV2 and the COVID Pandemic

1.2         SARS-CoV-2 Protein and RNA Structure

1.3         SARS-CoV-2 Infection and Immune Response

1.4         SARS-CoV-2 Mutations

1.4.1                     B.1.1.7 Variant

1.4.2                     B.1.351 Variant

1.4.3                     P.1 Variant

1.4.4      Rapid Spread of D614G Mutation Globally

1.4.5      Variants and Vaccine Efficacy

1.4.6      BNT162b2 mRNA Covid-19 Vaccination Effectiveness in Israel

1.4.7      Challenges of Mid-Term and Long-Term Mutations

1.5         Future of Living Alongside SARS-CoV-2

 

2.0         COVID Vaccines

2.1         Introduction

2.1.1      mRNA Vaccines

2.1.2      DNA Vaccines

2.1.3      Inactivated Vaccines

2.1.4      Live-Attenuated Vaccines

2.1.5      Recombinant Protein Vaccines

2.1.6      Viral Vector Vaccines

2.2         Pfizer/BioNTech BNT162b2 Vaccine

2.3         Moderna mRNA1273 Vaccine

2.4         CureVac CVnCoV Vaccine

2.5         AstraZeneca/Oxford AZD-1222 Vaccine

2.6         Johnson & Johnson’s JNJ-78436735 Vaccine

2.7         Novavax NVX-CoV2373 Vaccine

2.8         Gamaleya Sputnik V Vaccine

2.9         Sinovac Coronavac Vaccin

 

3.0         Clinical Trials

3.1         Introduction

3.2         Clinical Trials by Geographic Area

3.3         Clinical Trials by Phase

3.3.1      Phase III COVID Vaccine Trials

3.3.2      Phase II COVID Vaccine Trials

3.3.3      Phase I COVID Vaccine Trials

 

4.0         Molecular Diagnostics & PCR Testing

4.1         Introduction

4.2         PCR Diagnostic Testing Has Dominated the Space

4.3         Point of Care Testing

 

5.0         Market & Industry Analysis

5.1         Advance Purchase Agreements by Company

5.1.1                     Pfizer/BioNTech

5.1.2                     Moderna

5.1.3                     AstraZeneca/Oxford

5.1.4                     Novavax

5.1.5                     Sanofi/GSK

5.1.6                     J&J

5.1.7                     Curevac

5.2         Advance Purchase Agreements – Geographical Breakdown

5.2.1      USA

5.2.2      EU

5.2.2.1                  Distribution of Vaccines within the EU

5.2.3      Japan

5.2.4      Australia

5.2.5      China

5.2.6      UK

5.2.7      Russia

5.3         Price of Vaccines

5.4         Reasons for Booster Vaccine Requirements

 

6.0         COVID Vaccine Pandemic Market Analysis 2021

6.1         Market Revenue, Volume and Major Players

6.2         SubMarket by Major Player Breakdown

6.3         SubMarket by Technology Type

6.4         SubMarket by Geographical Breakdown

 

7.0         COVID Vaccine Market 2022 to 2026

7.1         Endemic Market Forecast to 2026

7.2         SubMarket by Geographical Breakdown to 2026

7.3         SubMarket by Major Player Breakdown to 2026

7.4         SubMarket by Vaccine Technology Breakdown to 2026

 

8.0         Future Outlook

 

List of Exhibits

 

Exhibit 1 Coronavirus Protein and RNA Structure

Exhibit 2 Common Symptoms Arising From SARS-CoV-2 Infection

Exhibit 3 Lifecycle of SARS-CoV2

Exhibit 4 Emergence of SARS-CoV-2 Mutations

Exhibit 5 SARS-CoV-2 Mutations – Current Variants of Concern

Exhibit 6 Emergence & Spread of SARS-CoV-2 Variants of Concern Globally

Exhibit 7 Mutations in the B.1.1.7 SARS-CoV-2 Variant Genome

Exhibit 8 Mutations in the B.1.351 SARS-CoV-2 Variant Genome

Exhibit 9 Mutations in the P.1 SARS-CoV-2 Variant Genome

Exhibit 10             Rapid Spread of D614G SARS-CoV-2 Variant over Time

Exhibit 11             SARS-CoV-2 Variants and Vaccine Efficacy

Exhibit 12             Neutralization of Variants B.1.1.7 and B.1.351 by Serum from mRNA-1273-Immunized Individuals

Exhibit 13             Israel Vaccination Cumulative Incidence of Five Outcomes

Exhibit 14             Israel COVID Vaccination Effectiveness during Three Time Periods

Exhibit 15             COVID Vaccine Types by Technology Platform

Exhibit 16             RNA Vaccine Technology, Benefits & Mechanism of Action

Exhibit 17             Advantages of mRNA Vaccines

Exhibit 18             Main COVID-19 Vaccines in the Market

Exhibit 19             Pfizer/BioNTech BNT162b2 Clinical Trial Stats

Exhibit 20             Moderna mRNA1273 Mechanism of Action

Exhibit 21             Moderna mRNA-1273 R&D and Trial Timeline

Exhibit 22             Moderna mRNA-1273 T Cell Immunogenicity Data

Exhibit 23             Moderna Distribution Infrastructure of mRNA1273

Exhibit 24             CureVac CVnCoV Vaccine Phase 1 Spike Binding Antibodies: Show Dose-Dependent Induction

Exhibit 25             CureVac Strategy to Track SARS-CoV-2 Evolution and Occurrence of New Mutations

Exhibit 26             CureVac CVnCoV Vaccine Shelf Life Allows for Established Cold-Chain Distribution

Exhibit  27            AstraZeneca Vaccine Mechanism of Action

Exhibit 28             Mechanism of Action of J&J’s COVID Vaccine

Exhibit 29             Novavax NVX-CoV2373 Vaccine Technology

Exhibit 30             Gamaleya’s Sputnik V Vaccine Double Adenoviral Vector Technology

Exhibit 31             Gamaleya’s Sputnik V Vaccine Immune Response over Time

Exhibit 32             Sinovac’s Coronavac Vaccine Technology

Exhibit 33             Clinical Trial Timelines for Main COVID Vaccine Candidates

Exhibit 34             Proportion of COVID Vaccines by Technology and Phase

Exhibit 35             Global SARS-CoV-2 and Vaccine Clinical Trials by Region

Exhibit 36             European SARS-CoV-2 and Vaccine Clinical Trials by Country

Exhibit 37             SARS-CoV-2 and Vaccine Clinical Trials in the USA by State

Exhibit 38             SARS-CoV-2 and Vaccine Clinical Trials in South America by Country

Exhibit 39             Comparison of Main COVID Vaccines Either with Emergency Approval or in Late Stage Development

Exhibit 40             Global SARS-CoV-2 and Vaccine Phase III Clinical Trials

Exhibit 41             Select Phase III Clinical Trials by Vaccine Type

Exhibit 42             Select Phase III Clinical Trials Investigating COVID Vaccines, Globally

Exhibit 43             Selected Phase II COVID Vaccine Trials Globally

Exhibit 44             Select Phase I Clinical Trials Investigating COVID Vaccines, Globally

Exhibit 45             Daily COVID-19 Tests per Thousand People in Selected Countries Over Time

Exhibit 46             USA Antigen and PCR Lab Based Test Volume in Millions, 2021

Exhibit 47             USA Antigen and PCR Lab Based Test Volume in Millions, 2021

Exhibit 48             USA Total Lab Based Test Volume in Millions, 2021

Exhibit 49             USA Antigen and Molecular POC Test Volume in Millions, 2021

Exhibit 50             USA Antigen, Molecular and Home POC Test Volume

Exhibit 51             Total USA POC Testing Volume in Millions

Exhibit 52             Vaccine Pre-Purchase Agreements by Country and Millions of the Population Covered

Exhibit 53             European Commission 27 Member States

Exhibit 54             Sputnik V Vaccine International Pre-Purchase Agreements by Country

Exhibit 55             Vaccine Capacity and Pre-Orders by Company

Exhibit 56             Vaccine Pre-Orders Country Dose number per Capita

Exhibit 57             Price Differences of Vaccines by Manufacturer and Geographic Region

Exhibit 58             Doses of COVID Vaccines Potentially Available in 2021 by Company in Billions

Exhibit 59             COVID Vaccine Market in 2021 by Company Revenue

Exhibit 60             COVID Vaccine Market in 2021 by Major Player Market Share

Exhibit 61             COVID Vaccine SubMarket Share by Technology – Volume of Doses 2021

Exhibit 62             COVID Vaccine SubMarket Share by Technology – Revenue (Billions) in 2021

Exhibit 63             COVID Vaccine SubMarket Share by Technology – Revenue Market Share in 2021

Exhibit 64             Comparison of COVID Vaccine Revenue from the EU, UK, USA and Japan by Major Company

Exhibit 65             COVID Vaccine Revenue by Geographic Area 2021

Exhibit 66             COVID Vaccine Revenue by Geographic Market Share 2021

Exhibit 67             COVID Vaccine Revenue EU Market Share by Company 2021

Exhibit 68             COVID Vaccine Revenue UK Market Share by Company 2021

Exhibit 69             COVID Vaccine Revenue USA Market Share by Company 2021

Exhibit 70             COVID Vaccine Revenue Japan Market Share by Company 2021

Exhibit 71             COVID Vaccine Market Revenue 2022-2026 Forecast

Exhibit 72             COVID Vaccine Market Revenue 2022-2026 Forecast by Geography

Exhibit 73             COVID Vaccine Market Revenue 2022-2026 Forecast by Major Player

Exhibit 74             COVID Vaccine Market Revenue 2022-2026 Forecast by Vaccine Technology